Compare BIO-TECHNE Corp (TECH) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? BIO-TECHNE Corp trades at $71.67 (market cap $11.16B), while iShares 20 Plus Year Treasury Bond ETF trades at $83.62. The key difference: BIO-TECHNE Corp pays a 0.45% dividend while iShares 20 Plus Year Treasury Bond ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| TECH | TLT | |
|---|---|---|
Market Cap | $11.16B | — |
Sector | Health | — |
52-Week High | $72.12 | $92.06 |
52-Week Low | $43.31 | $83.02 |
Enterprise Value | $11.24B | — |
Dividend Yield | 0.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $83.89, down 0.75% on the day. Technical indicators signal a bearish trend with moving averages showing selling pressure, while oscillators are neutral. The ETF has faced significant outflows amid rising interest rate concerns, with recent articles highlighting competition from cash ETFs and corporate bond alternatives offering higher yields. Dividend payments remain consistent but modest.
The outlook for TLT hinges on Federal Reserve policy shifts; potential rate cuts could boost long-term bonds, but persistent inflation risks may extend volatility. Investors face duration risk and opportunity cost versus shorter-term instruments. Wall Street sentiment is mixed, with some seeing value at current yields after steep declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
